Acumen pharmaceuticals reports financial results for the year ended december 31, 2023 and business highlights

Charlottesville, va., march 26, 2024 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos) (“acumen” or the “company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (aΒos) for the treatment of alzheimer's disease (ad), today reported financial results for the full year ended december 31, 2023 and provided a business update.
ABOS Ratings Summary
ABOS Quant Ranking